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Abstract
Importance: Research has indicated some shared pathogenic mechanisms between age-related macular degeneration
(AMD) and cardiovascular disease (CVD). However, results from prior epidemiologic studies have been inconsistent as to
whether AMD is predictive of future CVD risk.
Objective: To systematically review population-based cohort studies of the association between AMD and risk of total CVD
and CVD subtypes, coronary heart disease (CHD) and stroke.
Data Sources: A systematic search of the PubMed and EMBASE databases and reference lists of key retrieved articles up to
December 20, 2012 without language restriction.
Data Extraction: Two reviewers independently extracted data on baseline AMD status, risk estimates of CVD and methods
used to assess AMD and CVD. We pooled relative risks using random or fixed effects models as appropriate.
Results: Thirteen cohort studies (8 prospective and 5 retrospective studies) with a total of 1,593,390 participants with
155,500 CVD events (92,039 stroke and 62,737 CHD) were included in this meta-analysis. Among all studies, early AMD was
associated with a 15% (95% CI, 1.08–1.22) increased risk of total CVD. The relative risk was similar but not significant for late
AMD (RR, 1.17; 95% CI, 0.98–1.40). In analyses restricted to the subset of prospective studies, the risk associated with early
AMD did not appreciably change; however, there was a marked 66% (95% CI, 1.31–2.10) increased risk of CVD among those
with late AMD.
Conclusion: Whereas the results from all cohort studies suggest that both early and late AMD are predictive of a small
increase in risk of future CVD, subgroup analyses limited to prospective studies demonstrate a markedly increased risk of
CVD among people with late AMD. Retrospective studies using healthcare databases may have inherent methodological
limitations that obscure such association. Additional prospective studies are needed to further elucidate the associations
between AMD and specific CVD outcomes.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
blindness among older persons in the US and other developed
countries. About 9 million adults aged 40 years or older in the US
are affected by different forms and severity of AMD [1], and the
number of persons having AMD is projected to double by 2020
owing to the rapidly aging population [1]. AMD is categorized
into early- and late-stage AMD according to AMD signs and
severity. Most visual loss occurs in late AMD, which manifest itself
in two forms, neovascular AMD and central geographic atrophy
[2].
Cardiovascular disease (CVD), which includes both coronary
heart disease (CHD) and cerebrovascular disease (stroke), remains
the leading cause of deaths in both men and women globally. In
the US, 1 in 3 adults have one or more types of CVD [3].
Epidemiologic studies have identified a number of CVD risk
factors, among which age [4], ethnicity [5], obesity [6], cigarette
smoking [7], hypertension [8] and high cholesterol [9] have also
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e89600been associated with increased risk of AMD. In addition to
traditional CVD risk factors, recent studies have suggested that C-
reactive protein (CRP), a marker of systematic inflammation and
independent risk factor for CVD, is associated with AMD as well
[10,11]. Furthermore, common genetic variants (apolipoprotein E
[12,13], complement factor H [14,15]) have been linked to both
CVD and AMD, though not necessarily in the same manner. In
some studies [8,16,17], CVD has been shown as an independent
risk factor for AMD, and are consistent with the hypothesis that
AMD and CVD may share common underlying pathogenic
mechanisms [18].
However, it remains unclear if in some instances AMD may
manifest first and thus whether AMD might serve as an indicator
for future risk of CVD. Prior studies of this issue were inconsistent
and the work was underpowered to evaluate the potential
differential associations of early versus late AMD with CVD.
The goal of this study was to carry out a systematic review and
meta-analysis of population-based cohort studies to estimate the
risk of total CVD, as well as CVD subtypes, CHD and stroke,
associated with early AMD and late AMD.
Methods
Search Strategy and Eligibility Criteria
One investigator (JW) conducted a systematic literature search
of the PubMed and EMBASE databases and the reference list of
retrieved articles up to December 20, 2012. The following terms
were used for the search: (‘‘macular degeneration’’ or ‘‘maculop-
athy’’) and (‘‘cardiovascular diseases’’ or ‘‘heart disease’’ or
‘‘stroke’’ or ‘‘coronary disease’’) (detailed search terms available
in Table S1). No language restriction was applied. Two
investigators (JW, MU) independently screened all the retrieved
articles for inclusion and exclusion. We conducted this systematic
review according to the guidelines of Meta-analysis of Observation
Studies in Epidemiology (MOOSE) (Table S2) [19].
Studies were eligible for inclusion if they met the following
criteria: 1) the study design was a population-based cohort study;
2) the baseline exposure was AMD; 3) The outcome was CVD (not
CVD risk factors or biomarkers); 4) The study provided a
multivariate-adjusted effect estimate (hazard ratio, odds ratio or
relative risk) for the association of AMD with CVD. We defined
early AMD according to the Wisconsin age-related maculopathy
grading system (WARMGS) [20], as the presence of soft drusen
alone (distinct or indistinct), pigmentary abnormalities alone, or a
combination of these in the absence of late AMD signs. Late AMD
included the presence of neovascular AMD or central geographic
atrophy. For studies that divided AMD into neo- and non-
neovascular AMD types, we treated the non-neovascular AMD as
early AMD in the primary meta-analysis, because early AMD
accounted for at least 88% of the non-neovasular AMD cases [1].
We defined CVD as a composite outcome including CHD, CHD
deaths, stroke, stroke deaths, and other atherosclerotic events.
When multiple studies were published from the same cohort, we
included only the most up-to-date analyses in which the highest
number of CVD outcomes had accrued. A study that assessed two
different CVD subtypes was counted as two studies in analysis
unless it also assessed total CVD.
Data Extraction
Two investigators (JW, MU) independently extracted data using
a standardized electronic form. Discrepancies were resolved by
discussion with the senior investigator (DAS). For each included
study, we documented the title, study name, authors, publication
year, country, study design, sample size, race/ethnicity, mean age
and range, mean body mass index (BMI), proportion of men,
mean duration of follow-up, the number of subjects with AMD at
baseline (early and late AMD, respectively), AMD ascertainment
method, the number of CVD cases, CVD ascertainment method,
covariates adjusted for, risk estimates including 95% confidence
intervals. Two types of AMD assessment method were used by
included studies: in the prospective studies, retinal photographs
were taken and were graded according to WARMGS [20];
whereas in retrospective studies, AMD was identified from claims
data according to International Classification of Diseases codes,
Ninth Revision (ICD-9). Methods of CVD ascertainment also
differed between prospective and retrospective studies, with the
former based on self-report followed by medical record review and
the latter based on claims data and ICD-9 codes. If more than one
multivariable-adjusted relative risk (RR) was provided, we
extracted the effect estimate with the greatest adjustment for
potential confounders.
Statistical Analysis
We log transformed RRs and 95% CIs to obtain the
corresponding standard errors for the b–coefficients according to
the Greenland’s formula [21]. In the Rotterdam Eye Study where
RRs were reported across graded stage of AMD (stage 0–4, with
stage 1–3 being early AMD and 4 being late AMD) [22], we used
generalized least-squares trend estimation (GLST) [23] method to
estimate the log-linear dose-response slope within stage 0 to 3 to
approximate the overall RR associated with early AMD. The RR
provided for the fourth stage of AMD would then represent the
association of late AMD with CVD. The imputed RRs from the
Rotterdam Eye Study were then pooled with RRs from other
studies to derive an overall risk estimate using random-effects
models, which took into account both the within-study and
between-study variability. The I
2 statistic was used to evaluate the
heterogeneity between studies [24]. Fixed-effects models were only
used when the I
2 was below 30%. Of note, fixed-effects and
random-effects model yields exactly the same results when I
2=0%
(indicating no between-study heterogeneity).
To explore heterogeneity among studies, we used STATA
METAREG to examine if the risk estimates were significantly
different according to certain study-level characteristics, including
study design (prospective or retrospective studies), publication
year, study location, race/ethnicity (black/white, mostly white,
Asian and mixed), mean age, proportion of men, mean duration of
follow-up. In subgroup analyses, we further tested for the presence
of effect modification by method of AMD assessment, CVD
ascertainment and BMI.
We performed the primary meta-analyses separately for early
and late AMD in relation to total CVD. Subgroup analyses were
conducted to examine the associations of each with stroke and
CHD. We also conducted sensitivity analyses by excluding
retrospective studies from both primary and, if possible, subgroup
analyses. Publication bias was assessed by visual inspection of
funnel plots as well as by Begg’s and Egger’s tests [25]. All tests
were two-sided, and P,0.05 was considered as statistically
significant. We used STATA version 11 (StataCorp, College
Station, Texas) to perform all the statistical analyses.
Results
Study population
Of the 13 unique studies that met the inclusion criteria, 5 were
retrospective cohort studies [26–30] using healthcare claims
databases and 8 were prospective cohort studies [22,31–37]
(Figure 1). The 13 studies included 2 from Asia, 1 from Europe, 1
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cases (including 92,039 strokes and 62,737 CHDs) were identified
among 1,593,390 participants. The mean age of the study
populations at baseline ranged from 59.8 to 78.4 years, average
BMI ranged from 26.0 to 28.8 kg/m
2 and the proportion of men
varied from 34.4% to 60.3%. The mean duration of follow-up
varied from 2.0 to 13.6 years, with longer follow-up generally seen
in prospective studies (Table 1).
Early AMD with CVD
Across 10 studies with information on early AMD [22,26,27,32–
37], early AMD was significantly associated with a 15% (95% CI,
1.08–1.22) increased incidence of total CVD (Figure 2). How-
ever, substantial between-study heterogeneity was observed
(I
2=68%, p=0.001). Study design did not explain the heteroge-
neity (p for interaction, 0.90) Begg’s (p=0.93) and Egger’s tests
(p=0.81) for publication bias were not significant but a visual
inspection of the funnel plot revealed slight asymmetry, suggesting
possible publication bias (Figure 3). Restricting analysis to
prospective studies did not appreciably change the pooled RR
or reduce between-study heterogeneity (Figure 2).
With respect to stroke, the pooled RR associated with early
AMD was 1.11 (95% CI, 0.94–1.32) across 5 studies. After
excluding the one retrospective study, the RR was slightly
attenuated to 1.07 (95% CI, 0.79–1.45) (Table 2). As the
stratified analysis by stroke subtypes showed, there appeared to be
a slightly stronger association between AMD and risk of
intracerebral hemorrhage (RR, 1.29; 95% CI, 1.00–1.68) as
compared to cerebral infarction (RR, 1.14; 95% CI, 0.96–1.35)
(Table 2). With respect to CHD, early AMD was associated with
a significant 19% (95% CI, 1.05–1.35) increased risk of CHD
across 4 studies. After excluding the only retrospective study, the
RR was slightly higher but no longer significant (RR, 1.21; 95%
CI, 0.93–1.57) (Table 2).
Figure 1. Flowchart of literature search for meta-analysis. None.
doi:10.1371/journal.pone.0089600.g001
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Author Study name Subjects, Ethnicity Mean age
Mean
BMI, Men, Mean AMD, Late
AMD
assessment
(year) (country) No. (range), y kg/m
2 %
follow-up,
y No. AMD, %
Stroke
Ikram et al ARIC 12,216 White/black 59.9 28.4 44.2 13.0 591 2.5 Fundus
Photography
WARMGS
2012 USA (45.0-64.0)
Wieberdink et al 2011 Rotterdam
Netherlands
6,207 White 67.6 26.0 40.4 13.6 2,259 4.1 Fundus
Photography
Stage grading
a
(61.7-74.8)
Hu et al LHID 1,254 Asian 62.7 - 60.3 5.0 209 100 Claims database
2010 Taiwan (69.0-97.0) ICD-9
Sun et al CHS 2,228 White/Black 78.4 27.0 38.9 6.0 379 7.7 Fundus
Photography
WARMGS
2009 USA (69.0-97.0)
Tan et al BMES Australia 2,853 White 65.1 26.1 41.3 11.0 181 28.2 Fundus
Photography
WARMGS
2008 (49.0-97.0)
Liao et al Medicare USA 1,303,186 White/Black 75.0 - 40.0 2.0 137,838 19.7 Claims database
2008 ($65.0) ICD-9
Nguyen-Khoa et al LabRx 27,411 - 75.7 - 41.1 2.8 7,203 100 Claims database
2008 USA (50.0-95.0) ICD-9
Knudtson et al BDES 4,926 White 62.0 28.8 43.9 13.2 988 8.0 Fundus
Photography
WARMGS
2006 USA (43.0-84.0)
CHD
Fernandez MESA 6,233 Mixed 62.0 28.3 47.6 5.4 895 3.0 Fundus
Photography
WARMGS
2012 USA (45.0-84.0)
Golan MHS 68,218 White 68.5 - 41.5 11.0 6,546 - Claims database
2011 Israel ($65.0) ICD-9
Sun et al CHS 1,786 White/black 78.2 27.0 34.3 6.0 302 8.3 Fundus
Photography
WARMGS
2009 USA (69.0-97.0)
Nguyen-Khoa et al 2008 LabRx 27,411 - 75.7 - 41.1 2.8 7,203 100 Claims database
USA (50.0-95.0) ICD-9
Wong et al ARIC 11,414 White/black 59.8 28.5 42.3 8.0 555 2.7 Fundus
Photography
WARMGS
2007 USA (49.0-73.0)
Duan et al Medicare 1,445,677 White/black 76.0 - 40.0 2.0 157,579 19.6 Claims database
2007 USA ($65.0) ICD-9
Knudtson et al BDES 4,926 White 62.0 28.8 43.9 13.2 988 8.0 Fundus
Photography
WARMGS
2006 USA (43.0-84.0)
CVD
Macular Degeneration with Cardiovascular Disease
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e89600Table 1. Cont.
Author Study name Subjects, Ethnicity Mean age
Mean
BMI, Men, Mean AMD, Late
AMD
assessment
(year) (country) No. (range), y kg/m
2 %
follow-up,
y No. AMD, %
Fernandez MESA 6,233 Mixed 62.0 28.3 48.0 5.4 895 3.0 Fundus
Photography
WARMGS
2012 USA (45.0-84.0)
Tan et al BMES 2,853 White 65.1 26.1 41.3 11.0 181 28.2 Fundus
Photography
WARMGS
2008 Australia (49.0-97.0)
AREDS research AREDS 4,753 Mostly 69.0 27.5 44.2 6.5 4,753 20.1 Fundus
Photography
group 2004 USA white (55.0-81.0) AREDS
Author Outcome, Outcome ascertainment Adjustment for covariates Study design
(year) No.
Stroke
Ikram et al 619 Self-report confirmed by Age, sex, race, field center, mean ABP,
antihypertensive medication, fasting glucose,
Prospective
2012 medical record cholesterol, HDLC, triglyceride, BMI, atrial
fibrillation, white blood cell count,
Wieberdink et al 726 Database linkage and Age, sex, diabetes, SBP, antihypertensive
medication, smoking, total cholesterol,
Prospective
2011 medical record review HDLC, BMI, carotid artery plaques, CRP, and
alcohol
Hu et al 142 Claims database Age, sex, hypertension, diabetes, CHD,
hyperlipidemia, renal disease, monthly
Retrospective
2010 ICD-9 income, urbanization level, and geographic
region
Sun et al 198 Self-report confirmed by Age, sex, ethnicity, SBP and DBP,
hypertension, fasting glucose, diabetes,
Prospective
2009 medical record triglyceride, smoking (pack-years and
current), LDLC, CRP
Tan et al 99 Linkage with national death Age, sex, hypertension, diabetes, smoking,
and BMI
Prospective
2008 database
Liao et al 89,501 Medicare claims database Age, sex, race, hypertension, and diabetes Retrospective
2008 ICD-9
Nguyen-Khoa et al 549 Claims database Angina, cardiac arrhythmia, Charlson
comorbidity score, congestive heart failure,
Retrospective
2008 ICD-9 diabetes, heart disease, history of acute MI,
history of CVA, hyperlipidemia,
hypertension, and other cerebrovascular
disease (AMD and non-AMD were matched
on age, sex, geography and duration of
enrollment)
Knudtson et al 205 Death Certificate Age, sex, BMI, BMI squared, proteinuria, SBP,
and diabetes
Prospective
2006 ICD-9
CHD
Fernandez et al 278 Self-report confirmed by Race, hypertension, smoking, enrollment site,
CRP, education, diabetes, BMI, serum
Prospective
2012 medical record cholesterol, and LDLC
Golan 3,156 Claims database Age, sex, diabetes and hypertension Retrospective
2011 ICD-9
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Across 12 studies with information on late AMD [22,26–29,32–
34,36,37], the pooled RR for total CVD associated with late AMD
was 1.17 (95% CI, 0.98–1.40) (Figure 4). Substantial between-
study heterogeneity was evident (I
2=91%, p,.001). Which CVD
outcomes were assessed did not contribute to the heterogeneity (p
for interaction, 0.53). We found that mean age at baseline
significantly modified the association between late AMD and
incident CVD (p for interaction, 0.01). Higher risk was seen in
studies with mean participant age ,75 years, in which the pooled
RR was 1.80 (95% CI, 1.46–2.23), whereas in studies with mean
participant age $75 years, the RR was 0.90 (95% CI, 0.72–1.13).
Elevated risk of CVD among those with late AMD was also only
seen in studies with duration of follow-up greater than 5 years (.5
y: RR, 1.74, 95% CI, 1.42–2.41 versus #5 y: RR, 0.89, 95% CI,
0.71–1.12; p for interaction, 0.02). Both Begg’s (p=0.73) and
Egger’s (p=0.62) tests were not significant but a visual inspection
of funnel plot indicated potential publication bias (Figure 3). To
further explore between-study heterogeneity, we separately
analyzed the associations among the prospective and retrospective
studies. In the subgroup of 7 prospective studies, there was a strong
and significant association between late AMD and total CVD with
a RR of 1.66 (95% CI, 1.31–2.10) (Figure 4). Little heterogeneity
was found among prospective studies (I
2=0%, p=0.72). In
contrast, the pooled analysis among all retrospective studies
revealed substantial heterogeneity (RR, 0.99; 95% CI, 0.80–1.23;
I
2=97%), suggesting that it was mainly the retrospective studies
driving the overall between-study heterogeneity. Among prospec-
tive studies, the same pattern of effect modification by baseline
mean age persisted, although the test for interaction was not
significant likely due to a reduction in power for this test (data not
shown). Duration of follow-up was no longer a significant effect
modifier, but all prospective studies had at least 5 years of mean
follow-up. Funnel plot was fairly symmetric and tests for
publication bias were not significant (Figure 3).
Table 1. Cont.
Author Outcome, Outcome ascertainment Adjustment for covariates Study design
(year) No.
Sun et al 303 Self-report confirmed by Age, sex, ethnicity, SBP and DBP,
hypertension, fasting glucose, diabetes,
Prospective
2009 medical record triglyceride, smoking (pack-years and
current), LDLC, CRP
Nguyen-Khoa et al 584 Claims database Angina, cardiac arrhythmia, Charlson
comorbidities score, congestive heart failure,
Retrospective
2008 ICD-9 diabetes, heart disease, history of acute MI,
history of CVA, hyperlipidemia,
hypertension, and other cerebrovascular
disease (AMD and non-AMD were matched
on age, sex, geography and duration of
enrollment)
Wong et al 922 Self-report confirmed by Age, sex, race, field center, education, SBP,
DBP, diabetes, total cholesterol,
Prospective
2007 medical record triglyceride, glucose, HDLC, smoking (pack-
years), and alcohol
Duan et al 56,611 Medicare claims database Age, sex, race, hypertension and diabetes Retrospective
2007 ICD-9
Knudtson et al 883 Death Certificate ICD-9 Age, sex, BMI, BMI squared, ratio of total
cholesterol to HDLC, smoking, pulse,
Prospective
2006 diabetes, sedentary lifestyle, education, SBP
CVD
Fernandez et al 384 Self-report confirmed by Race, hypertension, smoking, enrollment site,
CRP, education, diabetes, BMI, serum
Prospective
2012 medical record cholesterol, and LDLC
Tan et al 183 Linkage with national death Age, sex, hypertension, diabetes, smoking,
and BMI
Prospective
2008 database
AREDS research 534 Medical record and death Age, sex, race, education, smoking, BMI,
diabetes, angina, cancer and hypertension
Prospective
group 2004 certificate
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; MESA, Multi-Ethnic Study of Atherosclerosis; CHS, Cardiovascular Health Study; BMES, Blue Mountains
Eye Study; BDES, Beaver Dam Eye Study; LHID, Longitudinal Health Insurance Database; LabRx, Ingenix LabRx Database; Medicare, Medicare beneficiaries databases;
MHS, Maccabi Healthcare Services; AREDS: Age-Related Eye Disease Study; WARMGS, Wisconsin age-related maculopathy grading system; ICD-9, International
Classification of Disease codes, Ninth Revision; ABP, Arterial blood pressure; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol; BMI,
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MI, myocardial infarction; CVA, cerebrovascular accident; CRP, C-reactive protein.
aAMD was graded by stage 0–4 (0, no AMD), a grading scheme similar to the WARMGS.
doi:10.1371/journal.pone.0089600.t001
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late AMD was 1.15 (95% CI, 0.74–1.78) based on 6 studies. When
the retrospective studies were excluded, the RR for stroke
associated with late AMD was statistically significant at 1.43
(95% CI, 1.02–2.00) (Table 2). We did not evaluate the
associations of late AMD with stroke subtypes as only 2 studies
[22,27] evaluated this association. The 2 studies exhibited opposite
direction of associations regarding cerebral infarction but the same
positive associations with intracerebral hemorrhage. Such differ-
ential association between late AMD and different stroke types is
consistent with what we observed for early AMD. With respect to
CHD, the association between late AMD and CHD was not
significant (RR, 1.12; 95% CI, 0.64–1.96) in the primary analysis,
though the RR was elevated when the two retrospective studies
were excluded (RR, 1.64; 95% CI, 0.75–3.61) (Table 2).
Discussion
In the present systematic review, both early and late AMD were
associated with a modest increased incidence of CVD when data
from both prospective and retrospective cohort studies were
summarized. Analyses restricted to the subset of prospective cohort
studies, however, identified a stronger 66% increased risk of CVD
among persons with late AMD. There was also a trend towards
increased risk of CHD and stroke among those with early AMD
and late AMD but findings were limited by a small number of
studies.
Subgroup analyses revealed that the association between late
AMD and risk of CVD was only evident among populations with a
mean age ,75 years. This observation might be explained by an
increase with aging in the prevalence of other CVD risk factors
and/or in the absolute risk of CVD. Alternatively, people with a
strong genetic predisposition to late AMD may have an earlier age
of onset, and may be the group more likely to have increased risk
of CVD due to genetic or other factors. Such a finding could also
be explained by selective mortality bias in that the removal of
susceptible persons results in falsely attenuated associations in the
older population. It is of interest that this finding is consistent with
results in the Blue Mountains Eye Study, in which late AMD was
significantly associated cardiovascular mortality among partici-
pants younger than 75 years old, but not in participants 75 years
or older [38].
A recent meta-analysis by Chakravarthy et al [39] has
investigated if some CVD risk factors and CVD itself are
predictive of the development of late AMD. In that study, CVD
was found to be only weakly and non-significantly associated with
future risk of late AMD among prospective cohort studies (RR,
1.22; 95% CI, 0.92–1.63). Therefore, whether CVD could be used
as a risk indicator for late AMD remains inconclusive. Our study,
on the other hand, demonstrated that in some cases when late
AMD manifests first, it might serve as a useful indicator of a higher
risk for future CVD events. Moreover, whereas Chakravarthy et
al. restricted their analysis to associations of CVD with late AMD,
we included early AMD cases and found a modest association
between early AMD and risk of future CVD. Thus, our work and
that published by Chakravarthy et al collectively support the
shared antecedents hypothesis between AMD and CVD. In our
study, the increasing magnitude of association with future CVD
from early to late AMD is biologically plausible, and, clinically,
implies that a cardiovascular risk assessment for AMD patients
Figure 2. Relative risks of total CVD associated with early AMD. Top panel represents forest plot among all relevant cohort studies. Bottom
panel represents forest plot among all relevant prospective cohort studies. Open data markers indicate the adjusted RR of CVD comparing persons
with early AMD to persons without early AMD. The size of the data markers represents the weight of the study. Diamond indicates the pooled RR.
a
The study evaluated CHD and stroke separately without providing an overall RR for total CVD.
doi:10.1371/journal.pone.0089600.g002
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PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e89600Figure 3. Funnel plots for the detection of public bias among studies that evaluated the associations of AMD with total CVD. The
vertical line across the X-axis is the log of the pooled RR. Dotted lines are pseudo 95% CIs corresponding to a given standard error. Each dot
represents one identified study. A symmetric distribution of dots around the vertical line indicates minimal publication bias. Figure 3A, early AMD
with CVD. Begg’s test, p=0.93; Egger’s test, p=0.81; Figure 3B, late AMD with CVD. Begg’s test, p=0.73; Egger’s test, p=0.62; Figure 3C, late AMD
with CVD among prospective studies. Begg’s test, p=0.76; Egger’s test, p=0.86.
doi:10.1371/journal.pone.0089600.g003
Table 2. The pooled relative risks for CVD subtypes in relation to early and late AMD.
Exposure Outcome Study type Data points, No. Summary RR (95% CI) P for heterogeneity I
2,%
Early AMD
Stroke All 5 1.11 (0.94, 1.32) ,0.001 83
Stroke Prospective 4 1.07 (0.79, 1.45) 0.02 71
*ICH All 3 1.29 (1.00, 1.68) 0.14 49
*CI All 3 1.14 (0.96, 1.35) 0.01 81
CHD All 4 1.19 (1.05, 1.35) 0.20 35
CHD Prospective 3 1.21 (0.93, 1.57) 0.10 56
Late AMD
Stroke All 6 1.15 (0.74, 1.78) ,0.001 92
Stroke Prospective 3 1.43 (1.02, 2.00) 0.27 24
CHD All 5 1.12 (0.64, 1.96) ,0.001 93
CHD Prospective 3 1.64 (0.75, 3.61) 0.21 36
*ICH, intracerebral hemorrhage; *CI, cerebral infarction.
doi:10.1371/journal.pone.0089600.t002
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detection of underlying CVD. Of note, the association between
AMD and future CVD has been adjusted for shared risk factors.
Therefore, the association may reflect some other aspects of shared
pathogenic processes, such as those due to diet and genetics. If
applied clinically, the positive predictive value of AMD for CVD
might be even higher, as it reflects a composite pathogenic process
of clinically observable as well as unknown or unmeasurable
underlying risk factors. However, more research is needed to
understand the possible utility of CVD screening among patients
with AMD.
Several mechanisms for observed associations of AMD with
CVD have been proposed. Chronic inflammation is a plausible
biologic mechanism for both AMD and CVD. The fact that
complement cascade activation plays a role in drusen formation
[14,40] and the identification of some genetic variants of
complement proteins as strong risk factors for AMD lends support
to a role of local inflammation in the pathogenesis of AMD.
However, although earlier epidemiologic studies suggested a
positive link between common AMD-associated variants in
complement factor H and CHD, a recent meta-analysis with a
large sample size and high statistical power did not confirm such
association, nor was any association found between AMD-
associated CFH variants and a wide range of CHD risk factors
or biomarkers except triglycerides [41]. These data suggest that
the relationship between AMD and CVD is probably more
complex than a single shared risk factor or even a single shared
biological pathway, and more work is clearly needed. Atheroscle-
rosis may also play a pathogenic role in the development of AMD
due to its effect on choroidal circulation and lipid deposition at
Bruch’s membrane [42]. Oxidized lipids would bind to macro-
phages, trigger downstream inflammatory cascade and result in
atherosclerotic lesions [43]. All these suggest that AMD is a
complex disorder stemming from interactions between inflamma-
tion, atherosclerosis and oxidative stress, pathogenic processes that
are also related to CVD.
In interpreting this meta-analysis, some limitations should be
noted. In primary analyses among all cohort studies, substantial
heterogeneity was evident and hence the pooled RRs should be
interpreted cautiously. We explored the sources of heterogeneity
and identified that study design contributed most of the
heterogeneity in the analysis of late AMD in relation to CVD.
Retrospective cohort studies conducted based on healthcare claims
databases were prone to a number of limitations. Residual and
unmeasured confounding was one of them, as such studies often
failed to account for confounding factors such as BMI, smoking,
physical activity and diet, which are important risk factors for
CVD. In addition, coding inaccuracies and lack of clinical
validation may have led to misclassification of both AMD and
CVD. These studies also had a shorter duration of follow-up, and
thus there may have been insufficient time for an increased risk of
CVD to become manifest. As a result, such studies may have been
biased in an unpredictable direction, as demonstrated by the
substantial heterogeneity when pooling RRs only among retro-
spective cohort studies. In contrast, there was no significant
between-study heterogeneity among prospective studies of late
AMD. This is expected, as prospective studies generally had better
adjustment for a wide range of potentially confounding factors,
longer duration of follow-up (ranging from 5 to 13 y), as well as
standardized procedures for AMD and CVD ascertainment.
Based on these observations, we think that the pooled risk
estimates from the subset of prospective cohort studies are likely to
be the most reliable and informative. However, restricting to
prospective studies did not effectively reduce the heterogeneity in
Figure 4. Relative risks of total CVD associated with late AMD. See footnote of Figure 2.
a,b The studies evaluated CHD and stroke separately
without providing overall RRs for total CVD.
doi:10.1371/journal.pone.0089600.g004
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inherent heterogeneity of early AMD with respect to varying stage
and severity and to the likely misclassification as a result of
detection bias – most early AMD are asymptomatic. Another
limitation of this meta-analysis is related to the different
components of total CVD, which may have different associations
with AMD. However, since the test for heterogeneity was
nonsignificant, pooling together all CVD events would greatly
increase the statistical power. A minor limitation was introduced
by the imputed RR by GLST in the Rotterdam Eye Study: the
resulting overall RR should only be interpreted as the RR of stroke
for per one level increase in AMD stage. However, since the HR
was null across each stage of early AMD in this study, we argue
that GLST-generated RR, although not ideal, could approximate
the true HR. With only 13 studies included for meta-analysis, our
findings may be prone to publication bias. Finally, our meta-
analysis had limited ability to perform reliable subgroup analyses
in relation to each CVD subtype. Prospective cohort studies
conducted in the younger elderly with large sample sizes, long
duration of follow-up and standardized protocol in AMD
assessments and CVD ascertainments are warranted to further
clarify the issues above.
Our meta-analysis also has several strengths. We built our
analyses on population-based cohort studies and excluded case-
control and cross-sectional analyses, which greatly reduced the
likelihood of selection bias and recall bias and established
temporality. We have included population-based cohort studies
with wide geographic locations and varied population character-
istics, which increased the generalizability of our results. In
addition, we have investigated separately the associations between
early and late AMD with CVD. The consistent findings and a
‘‘dose-response’’ relationship, as shown in the prospective studies,
not only increased the validity of our findings but also provided
additional clinically relevant information, as early AMD is the
predominant type of AMD in the older persons. Owing to the
relatively low prevalence of late AMD (1.5% among Americans 40
years of age or older [1]), most prospective cohort studies were not
able or underpowered to assess its association with CVD, let alone
with CVD subtypes, which necessitates pooled analysis with
enhanced statistical power, such as we conducted.
In conclusion, our meta-analysis based on best-available
evidence from prospective cohort studies indicates that early and
late AMD are independent predictors of future CVD, and the
association is much stronger for late AMD. Although retrospective
studies using healthcare databases had much higher statistical
power, the inherent methodological limitations may prohibit
making reliable inferences about associations. Additional prospec-
tive studies are still warranted to provide further insights into the
associations of AMD with CVD and individual cardiovascular
endpoints. Clinically, our study implies that an increase in cross-
disciplinary awareness among ophthalmologists, optometrists,
cardiologists, and other physicians of the link between these two
diseases could have beneficial health consequences for patients.
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